William Clay Faquin, M.D., Ph.D.
This page shows the publications co-authored by William Faquin and Sara Pai.
Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer Cytopathol. 2017 07; 125(7):529-533.
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. Ophthalmic Plast Reconstr Surg. 2020 Sep/Oct; 36(5):444-450.
New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathol. 2020 11; 128(11):782-791.
High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. Am J Ophthalmol. 2020 12; 220:128-139.
Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunol Immunother. 2019 Aug; 68(8):1273-1286.
Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. Am J Ophthalmol. 2019 04; 200:226-241.
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol. 2018 Mar; 29(1):59-67.
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. Cancer Res. 2017 11 15; 77(22):6365-6374.
Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. Ann Thorac Surg. 2017 Feb; 103(2):e123-e125.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.